MESABI TRUST

 MSBのチャート


 MSBの企業情報

symbol MSB
会社名 Mesabi Trust (MESABI TRUST)
分野(sector)   
産業(industry)   
業種 鉄鋼   原材料・素材(Materials)
概要 メサビ・トラスト(Mesabi Trust)(同信託)はロイヤルティー・トラストである。同信託はメサビ鉄山東部のミネソタ州バビットに位置する鉄鉱山(Peter Mitchell Mine)から収益を挙げる。同信託は、信託財産を保護・保全するほか、費用と負債の支払い後(提供)で信託の承認保有者のために、収入・収益を収集・分配する。信託契約により、同信託が行うロイヤルティーと費用の支払い以外の事業活動は禁止される。同信託鉱物権益の借主・オペレーターはCliffs Natural Resources Inc (Cliffs)の子会社であるNorthshore Mining Corporation (NMC)。Cliffs Natural Resources Incは鉄鉱製品の生産者である。同信託はMesabi Iron Companyが所有していた全部の権利を保有する。  メサビ・トラストは、米国の信託会社。ミネソタ州セントルイス郡に広がる土地に位置するメサビ鉄山において二つのプロジェクト「Peters Lease」と「Cloquet Lease」の投資を手掛ける。Peters Lease Landsの所有者として20%の利子を取得するほか、隣接する非鉱物生産地の所有者として100%のリ―ス手数料を所有。  
本社所在地 c/o Deutsche Bank Trust Company Americas Trust_Agency Services 60 Wall Street 16th Floor New York NY 10005 USA
代表者氏名
代表者役職名
電話番号 +1 212-250-6519
設立年月日 22463
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数
url www.mesabi-trust.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 43.82784
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 395.83070
売上高 (百万ドル) 45.17444
企業価値(EV) (百万ドル) 362.65384
当期純利益 (百万ドル) 43.82785
決算概要 BRIEF: For the nine months ended 31 October 2018 Mesabi Trust revenues increased 33% to $39.8M. Net income increased 33% to $38.8M. Revenues reflect Interest increase from $40K to $147K. Dividend per share increased from $1.98 to $2.55. Basic Earnings per Share excluding Extraordinary Items increased from $2.22 to $2.96.

 MSBのテクニカル分析


 MSBのニュース

   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd By Investing.com  2021/02/11 13:03:02 Investing.com
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd
   Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study  2021/02/11 05:41:00 Benzinga
Positive results from Mesoblast Limited’s (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the …
   AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre half year results  2021/02/11 04:46:40 The Australian Financial Review
On a big day of the interim profit reporting season, we have results from AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre. Find full reports and analysis here.
   Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others  2021/02/09 18:30:00 PR Newswire
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cell therapy market accounted for…
   Maxim Group Stick to Their Buy Rating for Mesoblast Ltd By Investing.com  2021/02/09 09:10:06 Investing.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd
   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd By Investing.com  2021/02/11 13:03:02 Investing.com
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd
   Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study  2021/02/11 05:41:00 Benzinga
Positive results from Mesoblast Limited’s (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the …
   AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre half year results  2021/02/11 04:46:40 The Australian Financial Review
On a big day of the interim profit reporting season, we have results from AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre. Find full reports and analysis here.
   Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others  2021/02/09 18:30:00 PR Newswire
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cell therapy market accounted for…
   Maxim Group Stick to Their Buy Rating for Mesoblast Ltd By Investing.com  2021/02/09 09:10:06 Investing.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd
   Dawson James Stick to Their Buy Rating for Mesoblast Ltd By Investing.com  2021/02/02 09:14:14 Investing.com
Dawson James Stick to Their Buy Rating for Mesoblast Ltd
   ASX climbs; Felix jumps on ASX debut  2021/01/11 20:37:41 The Australian Financial Review
Australian shares are trading higher, supported by gains for the major banks, ARB, Super Retail and Mesoblast. Software provider Felix jumps on its first day as listed ASX company but PolyNovo and Altium are under pressure. Miners are also lagging the market.
   Mesoblast (ASX:MSB) trial results boost shares : ASX closed 0.9% lower  2021/01/11 06:00:40 Bourse Data
11 Jan 2021 - The Australian sharemarket slid today closing 61 points down, or 0.9 per cent lower at 6,697. Shares in Resmed (ASX:RMD) did well today. Shares in Westgold Resources (ASX:WGX) dropped along with Perseus Mining (ASX:PRU). Mesoblast (ASX:MSB) reports that their rexlemestrocel-L drug has shown to be effective in a Phase 3 trial.
   Mesoblast tipped to need $US75m cash injection  2021/01/07 05:26:24 The Australian Financial Review
A leading healthcare analyst has warned Mesoblast faces cashflow problems in 2021 with no near-term significant revenue opportunity.
   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd  2020/12/18 13:15:37 Investing.com
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd

 関連キーワード  (鉄鋼 米国株 MESABI TRUST MSB )

鉄を主成分とする材料の総称。純鉄や鋼、鋳鋼、合金鋼、銑鉄、鋳鉄、フェロアロイなどがある。中国の過剰生産や安価な鋼材輸出とそれに伴う国際市況の低迷、鉄鉱石や原料炭価格など鉄鋼株を見るうえでポイントは多いが、一方で、国内では東京五輪を控えた建設需要の拡大、海外展開などにも注目したい。

 twitter  (公式ツイッターやCEOツイッターなど)